Business development, including investment in regenerative medicine and fertility treatment
First written in FY2022-Q1. 7 of 14 entries say "Advanced", first in FY2023. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「We are also working with medical institutions to develop a plan for providing Type 2 regenerative medicine and other medical care using umbilical cords and umbilical cord blood. In addition, together with iPS Portal Co., Ltd., we are considering the commercialization of manufacturing and storage services for autologous umbilical-cord-blood-derived iPS cells, while also working to expand the use of umbilical-cord-derived culture supernatant fluid in the cosmetics and private-pay medical care fields, thereby expanding opportunities to use stored cells.」
Business expansion into adjacent areas has taken concrete shape, including plans for providing second-class regenerative medicine services, iPS cell manufacturing and storage services, and cosmetic and elective medical applications for culture supernatant. - FY2026-H1AdvancedAnnual report
「Going forward, we will also pursue new development in related business fields by leveraging the infrastructure and network of the Group.」
The company made Milcare a consolidated subsidiary and gave specific shape to its policy of expanding into related businesses by leveraging the Group's infrastructure and network, centered on the family supernatant production service. - FY2025AdvancedAnnual report
「To date, we have invested in 6 companies, primarily in regenerative medicine and pregnancy and childbirth-related fields. During the cumulative first quarter period, we recognized extraordinary income of ¥136.939 million from the sale of shares in an investee company that was listed in June 2023. In February 2025, we also made a new investment in Smart Echo Co., Ltd., which operates the world's first subscription service for the home-use fetal ultrasound device “Pokemam” for pregnant women.」
The company described its investment track record involving 6 investee companies, the ¥136.939 million gain on the sale of shares in a listed investee company, and its new investment in Smart Echo in February 2025, giving specific shape to business development including investment and M&A. - FY2024-Q3AdvancedAnnual report
「Grace Group Co., Ltd., which provides egg-freezing and storage services and with which we formed a capital and business alliance in January 2021, saw its name recognition increase substantially after the Tokyo Metropolitan Government began subsidizing the costs of egg freezing in September last year.」
It was reported that Grace Group, an investment and alliance partner in the fertility treatment field, saw its name recognition increase substantially following the start of the Tokyo Metropolitan Government's egg-freezing cost subsidy program. - FY2024-Q2AdvancedAnnual report
「In addition, in August we entered into a capital and business alliance with Japan Medical Company Co., Ltd. (Chuo-ku, Tokyo; Representative Director and CEO Ohno Hideaki (大野秀晃)), which develops, manufactures and sells helmets using cutting-edge 3D-printing technology to correct irregularities in babies' head shapes and is targeting an early stock market listing. We are focusing on developing new projects, including M&A.」
As a new investment project, a capital and business alliance was formed with Japan Medical Company Co., Ltd., giving specific shape to the focus on developing new projects, including M&A. - FY2024-Q1AdvancedAnnual report
「In addition, because Cuorips Inc. (クオリプス株式会社), an investee company, was listed on the Tokyo Stock Exchange's Growth Market on 27 June this year, a gain on the sale of investment securities of ¥22.327 million was recognized as extraordinary income, among other factors,」
Cuorips Inc. (クオリプス株式会社), an investee company, was listed on the Tokyo Stock Exchange's Growth Market on 27 June 2023, and a gain on the sale of investment securities of ¥22.327 million was recognized in connection with the listing. - FY2023AdvancedAnnual report
「To further raise our cell storage rate as a percentage of all births in Japan from approximately 3%, our medium-term management target for the fiscal year ending March 2028, equivalent to approximately 20,000 stored cord blood specimens, from approximately 1% or 7,564 specimens in the current fiscal year, we are also actively promoting new businesses using treatment opportunities involving stem cells and products generated during cell culture, such as exosomes, with a view to launching them next fiscal year.」
Specific plans were presented for business development based on cell banking, including a storage-rate target for the fiscal year ending March 2028, expanded access to treatment and new businesses using exosomes and other products. - FY2023-Q3RestatedAnnual report
「We are also actively promoting new businesses ahead of their launch in the next fiscal year, including businesses for our storage customers using products generated during the culture of umbilical cord blood and umbilical cord cells, such as exosomes, and femtech businesses providing comprehensive support for women's health in collaboration with major operating companies.」
The company continues to promote a business for storage customers using products generated during cell culture and a femtech business ahead of their launch in the next fiscal year. - FY2023-Q2RaisedAnnual report
「Going forward, the company will actively promote new business development, including the development of regenerative medicine using menstrual-blood-derived stem cells as a new cell source, businesses using products from the culture of umbilical cord blood and umbilical cords, and femtech businesses providing comprehensive support for women’s health in cooperation with major operating companies.」
In addition to the previous business development and investment strategy in regenerative medicine, fertility treatment and related fields, new business areas were specified, including menstrual-blood-derived stem cells, products generated during the culture of umbilical cord blood and umbilical cord cells, and femtech. - FY2023-Q1RestatedAnnual report
「We operate a cell banking business involving perinatal tissue-derived cells, including “cord blood” and “umbilical cord,” for regenerative medicine and cell therapy, develop new treatments and regenerative medicine products using these cells, and conduct business development and investment in regenerative medicine, fertility treatment, childbirth, childcare and other fields based on these business platforms.」
The company continues to pursue a strategy of business development and investment in regenerative medicine, fertility treatment, childbirth, child-rearing and related fields, based on cell banking and the development of treatments and regenerative medicine products. - FY2022RestatedAnnual report
「We operate a cell banking business involving perinatal tissue-derived cells, including “cord blood” and “umbilical cord,” for regenerative medicine and cell therapy, develop new treatments and regenerative medicine products using these cells, and conduct business development and investment in regenerative medicine, fertility treatment, childbirth, childcare and other fields based on these business platforms.」
The company continues to pursue a strategy of business development and investment in regenerative medicine, fertility treatment, childbirth, child-rearing and related fields, based on cell banking and the development of treatments and regenerative medicine products. - FY2022-Q3Specific new business candidates identifiedAnnual report
「While growing our existing cell banking business, we are considering business development, including M&A, in fields such as data science, including AI, for preventive medicine, and the development of new products using stem cells, leveraging our network.」
In addition to the existing investment policy in regenerative medicine, fertility treatment and related fields, specific potential areas of expansion were described, including AI and data science for preventive medicine, new product development using stem cells and M&A. - FY2022-Q2RestatedAnnual report
「We operate a cell banking business involving cells derived from perinatal tissues, such as umbilical cord blood and umbilical cords, for regenerative medicine and cell therapy, develop new treatments and regenerative medicine products using these cells, and pursue business development, including investment in regenerative medicine, fertility treatment and related fields based on this business platform.」
Business development, including cell banking, the development of treatments and regenerative medicine products, and investment in regenerative medicine, fertility treatment and related fields, continues. - FY2022-Q1First statedAnnual report
「We operate a cell banking business involving cells derived from perinatal tissues, such as umbilical cord blood and umbilical cords, for regenerative medicine and cell therapy, develop new treatments and regenerative medicine products using these cells, and pursue business development, including investment in regenerative medicine, fertility treatment and related fields based on this business platform.」
For the first time, the company explicitly stated that it would pursue business development, including investment in regenerative medicine, fertility treatment and related fields, based on cell banking and research and development.